查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1138278

2022-2029 年全球静脉-静脉体外循环 (v-v ECLS) 市场

Global Veno-Venous Extracorporeal Life Support (VV ECLS) Devices Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

全球静脉-静脉体外循环 (v-v ECLS) 市场受到多种因素的推动，例如心肺和呼吸系统疾病的患病率不断提高、对心肺疾病的认识不断提高、对心肺监测和治疗系统的需求不断增加。促进因素推动了增长.

心肺和呼吸系统疾病的日益流行正在推动全球市场的增长。

心肺疾病是指影响心臟和肺部的多种疾病，心肺疾病一般有心血管疾病和慢性阻塞性肺疾病（COPD）两种，其患病率的上升是推动全球市场的增长。例如，根据英国心臟基金会的数据，2020 年将有大约 168,319 人死于心血管疾病。由于人口老龄化、可支配收入增加、生活方式改变和吸烟等多种因素，心肺疾病呈上升趋势。10亿人，预计到2050年将达到21亿人。然而，烟草消费每年导致全球超过 800 万人死亡，其中 700 万人归因于直接使用，120 万人归因于非吸烟者接触二手烟。我在这里。静脉-静脉体外循环 (v-v ECLS) 有助于通过适当的干预将患者的身体维持在正常水平。这些装置在新生儿期显示出良好的效果，有助于维持急性呼吸窘迫综合征 (ARDS) 和单心室生理。截至 2022 年 4 月，国际上有 172,853 名患者使用外部生命支持系统 (ECLS)，其中包括 46,698 名新生儿、93,091 名成人和 33,064 名年龄较大的儿童。 2021年註册ELSO中心的数量将达到543个，2021年ECLS的使用量将达到17,777个，在过去几年中呈现急剧增长。

并发症和熟练专业人员的短缺正在阻碍全球静脉-静脉体外循环 (v-v ECLS) 市场的发展。

但是，与外部生命支持设备相关的一些并发症，例如出血、感染和技术故障，加上设备的高成本和缺乏熟练的专业人员，阻碍了市场的增长。

COVID-19 影响分析

由于 COVID-19 是一种导致呼吸困难的严重急性呼吸综合征，而体外膜肺氧合 (ECMO) 是一种为肺部提供长期呼吸支持的体外技术，COVID-19 的爆发导致对体外膜肺氧合（ECMO），对全球市场的增长产生了积极影响。例如，根据体外生命支持组织的数据，13,988 名确诊的 COVID-19 患者至少在 90 天前开始了 ECMO。

全球静脉-静脉体外循环 (v-v ECLS) 市场报告将提供对大约 40 多个市场数据表、45 多个数字和 200 多页（大约）的访问。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 心脑血管疾病增加
      • 老年人口增加
      • 市场策略
    • 约束因素
      • 缺乏熟练的专业人员
      • 相关并发症
    • 商机
    • 影响分析

第五章行业分析

  • 波特五力分析
  • 供应链分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按产品类型

  • 单心室装置
  • 脑室装置

第 8 章最终用户

  • 医院
  • 医务室
  • 门诊手术中心 (ASC)
  • 其他

第 9 章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 10 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准

第 11 章公司简介

  • Medtronic, Plc
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • MAQUET Holding B. V. & Co. KG（Getinge Group）,
  • Microport Scientific Corporation,
  • Sorin Group,
  • Nipro Medical Corporation,
  • Terumo Cardiovascular Systems Corporation,
  • MedosMedizintechnik AG

第12章 DataM

简介目录
Product Code: DMMD2108

Market Overview

Veno-Venous Extracorporeal Life Support (VV ECLS) Devices Market is expected to grow at a high CAGR of 9.4% during the forecasting period (2022-2029).

Extracorporeal life support (ECLS), also known as extracorporeal membrane oxygenation (ECMO), is an extracorporeal technique that provides prolonged cardiac and respiratory support to the heart and lungs which are not able to provide an adequate amount of gas exchange or perfusion to sustain life. The technology for ECLS is derived from cardiopulmonary bypass, which provides shorter-term support with arrested native circulation.

In venovenous (VV) ECLS, cannulae are placed in the right common femoral vein for drainage and the right internal jugular vein for infusion. Alternatively, a dual-lumen catheter is inserted into the right internal jugular vein, draining blood from the superior and inferior vena cavae and returning it to the right atrium.

Market Dynamics

The global veno-venous extracorporeal life support (VV ECLS) devices market is growing due to several driving factors such as increasing the prevalence of cardiopulmonary disease & respiratory disorders and, raising awareness of the cardiopulmonary disease and increasing demand for cardiopulmonary monitoring and treatment system.

The increasing prevalence of cardiopulmonary disease & respiratory disorders is propelling the global market growth.

Cardiopulmonary disease refers to a range of diseases that affect the heart and the lungs, there are two common types of cardiopulmonary conditions: cardiovascular disease; and chronic obstructive pulmonary disorder (COPD), and their growing prevalence is driving the global market growth. For instance, according to the British Heart Foundation, around 168,319 people died from CVD in 2020. Cardiopulmonary diseases are rising due to several factors, such as the growing geriatric population, rising disposable income, changing lifestyles, smoking, and others; for instance, according to the world health organization, in 2020, there were 1 billion people aged 60 and above in 2020 and is estimated that by 2050 it will reach 2.1 billion. However, tobacco consumption is the cause behind over 8 million deaths each year globally, of which 7 million are due to direct use, and 1.2 million are because of non-smokers exposed to secondhand smoke. The Venovenous extracorporeal life support (VV ECLS) devices help the patients maintain the body to a normal level through appropriate intervention. These devices have shown favorable neonatal results and help maintain acute respiratory distress syndrome (ARDS) and single-ventricle physiology. As of April 2022, 172,853 patients had been placed on extracorporeal life support (ECLS) internationally, of which 46,698 were neonates, 93,091 were adults, and 33,064 were older children. The number of registered ELSO centers and their yearly use of ECLS increased precipitously in the last few years to 543 centers in 2021 and 17777 runs in 2021, respectively.

The complications and lack of skilled professionals hinder the global Veno-venous extracorporeal life support (VV ECLS) device market growth.

However, several complications associated with extracorporeal life support devices, such as bleeding, infections, and technical failures, coupled with the high cost of the devices and lack of skilled professionals, hinder the market's growth.

COVID-19 Impact Analysis

As COVID-19 is a severe acute respiratory syndrome that causes difficulty in breathing, and since extracorporeal membrane oxygenation (ECMO) is an extracorporeal technique that provides prolonged respiratory support to the lungs, the outburst of COVID-19 caused a rise in the demand for the extracorporeal membrane oxygenation (ECMO) therefore positively impacting the global market growth. For instance, according to the Extracorporeal Life Support Organization, 13988 Confirmed COVID-19 patients initiated ECMO at least 90 days ago.

Segment Analysis

Veno-venous extracorporeal life support (VV ECLS) devices are predicted to have a high demand during the forecast period (2022-2029).

The veno-venous extracorporeal life support (VV ECLS) devices market is segmented into the hindergle-ventricular device and biventricular device by product type. Among these, the venovenous extracorporeal life support (VV ECLS) devices in single-ventricle patients have shown increased market share in 2021 and are estimated to grow significantly over the forecast period. Single-site dual-lumen cannulas are used in infants, children, and adults. This approach incorporates drainage and reinfusion lumens into one unit inserted through the right internal jugular vein (RIJV). However, the venovenous ECLS has a substantial risk in patients with single-ventricle disorder due to coronary, pulmonary, and cerebral circulations. Biventricular devices supported with a paracorporeal pulsatile device are an efficient bridge to recovery for patients with fulminant myocarditis-related cardiogenic shock.

Geographical Analysis

North America is predicted to command the global Veno-venous Extracorporeal Life Support (VV ECLS) Devices market.

North America is dominating the global veno-venous extracorporeal life support (VV ECLS) devices market, accounting for the largest market share in 2021, owing to the rising prevalence of cardiopulmonary diseases, growing aging population, and active intervention by the government like the "Million Hearts" initiative by U.S. government to spread awareness about risk associated with cardiopulmonary diseases. According to the CDC, every 34 seconds, a U.S. American dies because of cardiovascular disease; in 2020, 697,000 American deaths were caused by cardiovascular disease. The North American VV ECLS market is expected to grow rapidly over the forecast period, owing to the rising demand for new innovative products. Terumo Cardiovascular Systems Corporation has refined existing technology while manufacturing CAPIOX FX Oxygenator.

Competitive Landscape

The veno-venous extracorporeal life support (VV ECLS) devices market is competitive with few major players. Some of the major players in the global veno-venous extracorporeal life support (VV ECLS) devices market include Medtronic, Plc, MAQUET Holding B. V. & Co. KG (Getinge Group), Microport Scientific Corporation, Sorin Group, Nipro Medical Corporation, Terumo Cardiovascular Systems Corporation, MedosMedizintechnik AG, among others. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations contributing to the veno-venous extracorporeal life support (VV ECLS) devices market globally. For instance, on July 12, 2022, Medtronic announced a co-promotion agreement with CathWorks, with an acquisition plan. Also, on 02 Jun 2022, Hemovent achieved MDSAP Certificate for the United States and Canada.

Medtronic, Plc.

Overview:

Medtronic plc is Ireland based American medical device company. Medtronic was founded in 1949 and is headquartered in Minneapolis, Minnesota, United States. Medtronics deals with four different businesses: the Minimally Invasive Therapies Group, the Diabetes Group, the Restorative Therapies Group, and the Cardiac and Vascular Group.

Product Portfolio:

The product portfolio of Medtronic, Plc. The product portfolio for veno-venous extracorporeal life support (VV ECLS) devices contains Nautilus Smart ECMO Module, Nautilus ECMO Oxygenator, Crescent RA Jugular Dual Lumen Catheter and Crescent Jugular Dual Lumen Catheter.

The global veno-venous extracorporeal life support (VV ECLS) devices market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Growing Prevalence of Cardio Vascular Diseases
      • 4.1.1.2. Growing Geriatric Population
      • 4.1.1.3. Market Strategies
    • 4.1.2. Restraints
      • 4.1.2.1. Lack of Skilled Professional
      • 4.1.2.2. Associated Complication
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
    • 7.1.2. Market Attractiveness Index, By Product Type Segment
  • 7.2. Single-ventricular device
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Biventricular device

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 8.1.2. Market Attractiveness Index, By End User Segment
  • 8.2. Hospitals
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Clinics
  • 8.4. Ambulatory Surgical Centers (ASCs)
  • 8.5. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. The U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. The U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Product Benchmarking

11. Company Profiles

  • 11.1. Medtronic, Plc
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. MAQUET Holding B. V. & Co. KG (Getinge Group),
  • 11.3. Microport Scientific Corporation,
  • 11.4. Sorin Group,
  • 11.5. Nipro Medical Corporation,
  • 11.6. Terumo Cardiovascular Systems Corporation,
  • 11.7. MedosMedizintechnik AG

LIST NOT EXHAUSTIVE

12. DataM

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us